㰀栀琀洀氀㸀 
㰀氀椀渀欀 爀攀氀㴀∀猀琀礀氀攀猀栀攀攀琀∀ 琀礀瀀攀㴀∀琀攀砀琀⼀挀猀猀∀ 栀爀攀昀㴀∀猀琀礀氀攀⸀挀猀猀∀⼀㸀 
㰀戀漀搀礀㸀 
Centre de Référence des Rhumatismes Inflammatoires et Maladies Autoimmunes Systémiques Rares de l’Enfant (RAISE) / 2017 
 
56 
Time 
to 
treatment 
as 
an 
important factor for the response to 
methotrexate 
in 
juvenile 
idiopathic arthritis. Arthritis Care Res 2009; 61:46–51 Traitements  
Beukelman T, Patkar NM, Saag 
KG, 
American 
Rheumatology 
College 
of 
recommendations 
for 
arthritis: 
initiation 
and 
safety 
monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 
(Hoboken). 
Apr;63(4):465–82.  2011 
Davies R, Gaynor D, Hyrich KL, 
Pain 
therapy 
juvenile 
individual 
arthritis 
subtypes: Semin 
Arthritis 
2017 
Foell 
D, 
Wulffraat 
Frosch 
M, 
Gerss 
J, 
et 
al. 
Methotrexate withdrawal at 6 vs 12 arthritis 
in 
remission: 
JAMA. 
2010 Apr 7;303(13):1266–73.  Ringold 
Colbert 
RA, DeWitt EM, Lee T, Onel K, et Rheumatology 
treatment 
plans for new-onset polyarticular juvenile 
idiopathic 
(Hoboken). 
2014 Jul;66(7):1063–72.  Traitements 
des 
formes 
polyarticulaires graves Tynjälä 
P, 
Vähäsalo 
P, 
Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination very 
juvenile 
early 
polyarticular 
idiopathic 
randomised 
open-label 
clinical trial. Ann Rheum Dis. 2011 Sep;70(9):1605–12.  Wallace 
Spalding 
Giannini 
Hashkes 
Trial 
of 
therapy juvenile Arthritis idiopathic 
Rheum. 
Jun;64(6):2012–21. Infiltrations intra-articulaires 
Ravelli 
van 
versus 
corticosteroids 
intra-articular 
plus 
methotrexate multicentre, 
Atteinte oculaire 
Biester 
al. 
Adalimumab 
therapy 
Ophthalmol. 
2007 Mar;91(3):319–24.